EA200100610A1 - Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты) - Google Patents
Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты)Info
- Publication number
- EA200100610A1 EA200100610A1 EA200100610A EA200100610A EA200100610A1 EA 200100610 A1 EA200100610 A1 EA 200100610A1 EA 200100610 A EA200100610 A EA 200100610A EA 200100610 A EA200100610 A EA 200100610A EA 200100610 A1 EA200100610 A1 EA 200100610A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nicotine
- conjugates
- hapten
- antibodies
- prevention
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 4
- 229960002715 nicotine Drugs 0.000 abstract 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 4
- 206010057852 Nicotine dependence Diseases 0.000 abstract 2
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/816—Alkaloids, amphetamines, and barbiturates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Abstract
Новые конъюгаты гаптен-носитель способны индуцировать образование in vivo антител, которые специфически связывают никотин. Данные конъюгаты содержат никотиновый гаптен, конъюгированный с иммуногенным белком-носителем. Новые конъюгаты сохраняют хиральность никотина в его природном (S)-(-)-состоянии и имеют хорошие характеристики стабильности. Конъюгаты используют для приготовления вакцин для активной иммунизации, которые применяют для профилактики и лечения никотиновой аддикции. Антитела, образующиеся в ответ на конъюгат никотиновый гаптен-носитель, используют для пассивной иммунизации. Данные антитела вводят для профилактики и лечения никотиновой аддикции.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/201,800 US6232082B1 (en) | 1998-12-01 | 1998-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
PCT/US1999/028272 WO2000032239A1 (en) | 1998-12-01 | 1999-12-01 | Hapten-carrier conjugates for treating and preventing nicotine addiction |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100610A1 true EA200100610A1 (ru) | 2002-04-25 |
EA004956B1 EA004956B1 (ru) | 2004-10-28 |
Family
ID=22747358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100610A EA004956B1 (ru) | 1998-12-01 | 1999-12-01 | Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты) |
Country Status (26)
Country | Link |
---|---|
US (7) | US6232082B1 (ru) |
EP (3) | EP1512414A1 (ru) |
JP (2) | JP4971542B2 (ru) |
KR (1) | KR100656836B1 (ru) |
CN (2) | CN1220521C (ru) |
AT (1) | ATE279211T1 (ru) |
AU (1) | AU763001B2 (ru) |
BR (1) | BR9915852A (ru) |
CA (1) | CA2352765C (ru) |
DE (1) | DE69921178T2 (ru) |
DK (1) | DK1135166T3 (ru) |
EA (1) | EA004956B1 (ru) |
ES (1) | ES2229800T3 (ru) |
HK (3) | HK1042428B (ru) |
HU (1) | HUP0104365A3 (ru) |
IL (2) | IL143474A0 (ru) |
ME (1) | MEP34208A (ru) |
MX (1) | MXPA01005511A (ru) |
NO (1) | NO331998B1 (ru) |
NZ (1) | NZ512103A (ru) |
PL (1) | PL199253B1 (ru) |
PT (1) | PT1135166E (ru) |
RS (1) | RS51273B (ru) |
TR (1) | TR200102411T2 (ru) |
WO (1) | WO2000032239A1 (ru) |
ZA (1) | ZA200104477B (ru) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
WO2002058635A2 (en) * | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Nicotine immunogens and antibodies and uses thereof |
SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
US20030148260A1 (en) * | 2001-08-07 | 2003-08-07 | Bernard Levin | Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy |
CA2477268A1 (en) * | 2002-03-01 | 2003-10-09 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
EP1523334A2 (en) * | 2002-07-18 | 2005-04-20 | Cytos Biotechnology AG | Hapten-carrier conjugates and uses thereof |
US20040115244A1 (en) * | 2002-12-17 | 2004-06-17 | Holgate Eric Jamison | Methods and compositions for nicotine replacement therapy |
ATE359075T1 (de) | 2002-12-20 | 2007-05-15 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
WO2005040338A2 (en) * | 2003-05-21 | 2005-05-06 | The Scripps Research Institute | Constrained alkaloid immunogens and antibodies and uses thereof |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
US7220842B2 (en) * | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
US7678551B2 (en) * | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
WO2006091796A2 (en) * | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
WO2007064478A2 (en) * | 2005-11-28 | 2007-06-07 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US7547712B2 (en) * | 2006-02-27 | 2009-06-16 | Nabi Biopharmaceuticals | Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women |
WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
EP2007435B1 (en) | 2006-03-31 | 2019-12-18 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
EP1849780A1 (en) | 2006-04-21 | 2007-10-31 | De Staat der Nederlanden, vert. door de minister van VWS | Vaccine against nicotine addiction |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
EP2019691B1 (en) | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
US9381477B2 (en) * | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US20100144845A1 (en) * | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ(アミノ酸)ターゲッティング部分 |
WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
CN105770878A (zh) | 2007-10-12 | 2016-07-20 | 麻省理工学院 | 疫苗纳米技术 |
CN101878228A (zh) * | 2007-11-29 | 2010-11-03 | 赛托斯生物技术公司 | 尼古丁特异性人单克隆抗体 |
EP2065398A1 (en) * | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
WO2009149252A1 (en) * | 2008-06-04 | 2009-12-10 | Cornell University | Vaccines for prevention and treatment of addiction |
CA2727617A1 (en) * | 2008-06-13 | 2009-12-17 | Nabi Biopharmaceuticals | Smoking cessation kit and method |
US20110182918A1 (en) | 2008-06-13 | 2011-07-28 | Nabi Biopharmaceuticals | Personalized drug treatment and smoking cessation kit and method |
CA2731494A1 (en) * | 2008-08-08 | 2010-02-11 | Novartis Ag | Process for the preparation of nicotine-based haptens |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
AU2009325926B2 (en) | 2008-12-09 | 2013-05-16 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
TW201109031A (en) * | 2009-07-31 | 2011-03-16 | Nabi Biopharmaceuticals | Method and kit for treating nicotine addiction |
KR101873179B1 (ko) * | 2009-08-26 | 2018-06-29 | 셀렉타 바이오사이언시즈, 인크. | T-세포 도움을 유도하는 조성물 |
WO2011031327A2 (en) * | 2009-09-14 | 2011-03-17 | The Scripps Research Institute | Nicotine haptens, immunoconjugates and their uses |
US20110182831A1 (en) * | 2010-01-25 | 2011-07-28 | Aradigm Corporation | Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use |
US9682133B2 (en) | 2010-03-17 | 2017-06-20 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
WO2011123042A1 (en) * | 2010-04-01 | 2011-10-06 | Independent Pharmaceutica Ab | Vaccination procedure and products for use therein |
GB201006324D0 (en) | 2010-04-15 | 2010-06-02 | Glaxosmithkline Biolog Sa | Vaccine |
AU2011258171B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
TWI455722B (zh) | 2010-06-04 | 2014-10-11 | Pfizer Vaccines Llc | 用於預防或治療菸鹼成癮之共軛體 |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
US20140039063A1 (en) * | 2011-01-04 | 2014-02-06 | National Jewish Health | Leukotrienes and asthma exacerbation risk |
WO2012138774A2 (en) | 2011-04-04 | 2012-10-11 | University Of Iowa Research Foundation | Methods of improving vaccine immunogenicity |
CA2843274A1 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
WO2013130393A1 (en) | 2012-02-28 | 2013-09-06 | Cornell University | Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation |
WO2013154744A1 (en) * | 2012-04-13 | 2013-10-17 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
TWI600905B (zh) * | 2012-09-21 | 2017-10-01 | 國立臺灣師範大學 | 聚合半抗原成為免疫原的技術方法 |
US9303013B2 (en) | 2014-05-16 | 2016-04-05 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
EP3145920B1 (en) * | 2014-05-19 | 2019-09-18 | The Scripps Research Institute | Enantiopure haptens for nicotine vaccine development |
CN104402992B (zh) * | 2014-11-28 | 2018-09-18 | 杭州安旭科技有限公司 | 一种合成大麻抗原的合成方法及合成大麻抗原的应用 |
WO2016116477A1 (en) * | 2015-01-20 | 2016-07-28 | Universiteit Antwerpen | Neuregulin in the treatment of fibrotic disorders |
CN106496309A (zh) * | 2016-11-24 | 2017-03-15 | 北京开景基因技术有限公司 | 微球抗原及其制备方法以及抗可替宁抗体的制备方法 |
WO2018231706A1 (en) | 2017-06-11 | 2018-12-20 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
MX2020001725A (es) | 2017-08-15 | 2020-08-20 | BliNK Biomedical | Anticuerpos de fijacion a nicotina novedosos. |
CN108362891B (zh) * | 2017-12-27 | 2020-09-25 | 北京勤邦生物技术有限公司 | 一种泼尼松的磁免疫化学发光检测试剂盒及其应用 |
US11333372B2 (en) | 2018-03-09 | 2022-05-17 | Scot Matthew Duncan | Energy recovery high efficiency dehumidification system |
CN112512549A (zh) | 2018-06-06 | 2021-03-16 | 安蒂多特疗法公司 | 改善循环和治疗心血管疾病的方法 |
KR102237349B1 (ko) | 2019-10-23 | 2021-04-07 | 한국과학기술연구원 | 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US3888886A (en) * | 1972-06-08 | 1975-06-10 | Mobil Oil Corp | Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst |
US4045420A (en) | 1973-05-29 | 1977-08-30 | Syva Company | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof |
US3888866A (en) | 1973-06-01 | 1975-06-10 | Syva Co | Nitrogen derivatives of benzoyl ecgonine |
US4053459A (en) | 1975-09-24 | 1977-10-11 | Hoffmann-La Roche Inc. | Antibody specific to methaqualone and its metabolites |
US4235864A (en) | 1978-04-10 | 1980-11-25 | Research Corporation | Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites |
US4376825A (en) | 1979-05-07 | 1983-03-15 | Syva Company | Enzyme amplification compounds for assays for androgens |
US4666837A (en) | 1982-05-24 | 1987-05-19 | Smithkline-Rit | DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits |
SU1123704A1 (ru) | 1983-04-08 | 1984-11-15 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | Способ получени конъюгированных антигенов |
EP0194158A3 (en) | 1985-03-08 | 1988-02-24 | Baylor College of Medicine | Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays |
US5019384A (en) | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
US4791067A (en) | 1987-06-25 | 1988-12-13 | Fisher Scientific Co. | Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent |
DE3884731D1 (de) | 1987-10-09 | 1993-11-11 | Ube Industries | Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin. |
US5268276A (en) | 1988-09-16 | 1993-12-07 | Jan Holmgren | Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides |
EP0363041A1 (en) | 1988-09-21 | 1990-04-11 | Ube Industries, Ltd. | Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine |
GB9001694D0 (en) | 1990-01-25 | 1990-03-28 | Therapeutic Antibodies Inc | Immunogenic compositions |
CH678394A5 (ru) | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
US5290784A (en) * | 1991-07-18 | 1994-03-01 | Yueqian Qu | Aconitane derivatives used as a medication to treat addiction |
US5233042A (en) | 1991-12-16 | 1993-08-03 | Biosite Diagnostics, Inc. | Cocaine derivatives |
US5283066A (en) | 1992-02-19 | 1994-02-01 | Development Center For Biotechnology | Method of stimulating an immune response by using a hapten |
DE4216133A1 (de) | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
WO1993023076A1 (en) | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
DE69332637T2 (de) | 1993-03-04 | 2003-10-23 | Matsushita Electric Ind Co Ltd | Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers |
US5375414A (en) | 1993-10-04 | 1994-12-27 | Ford Motor Company | Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control |
WO1995027786A1 (en) | 1994-04-08 | 1995-10-19 | Immulogic Pharmaceutical Corporation | Pharmaceutical formulations for treating japanese cedar pollen allergy |
US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5876727A (en) | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
WO1996030049A2 (en) | 1995-03-31 | 1996-10-03 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy |
US5773003A (en) | 1995-03-31 | 1998-06-30 | Immulogic, Inc. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US6455047B1 (en) * | 1997-09-19 | 2002-09-24 | Serex, Inc. | Methods to improve immunogenicity of antigens and specificity of antibodies |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
-
1998
- 1998-12-01 US US09/201,800 patent/US6232082B1/en not_active Expired - Fee Related
-
1999
- 1999-12-01 MX MXPA01005511A patent/MXPA01005511A/es not_active IP Right Cessation
- 1999-12-01 BR BR9915852-3A patent/BR9915852A/pt not_active IP Right Cessation
- 1999-12-01 NZ NZ512103A patent/NZ512103A/en not_active IP Right Cessation
- 1999-12-01 KR KR1020017006805A patent/KR100656836B1/ko not_active IP Right Cessation
- 1999-12-01 PT PT99964009T patent/PT1135166E/pt unknown
- 1999-12-01 CN CNB998139564A patent/CN1220521C/zh not_active Expired - Fee Related
- 1999-12-01 EP EP04024278A patent/EP1512414A1/en not_active Withdrawn
- 1999-12-01 HU HU0104365A patent/HUP0104365A3/hu unknown
- 1999-12-01 EP EP10179154A patent/EP2324855A1/en not_active Withdrawn
- 1999-12-01 EA EA200100610A patent/EA004956B1/ru not_active IP Right Cessation
- 1999-12-01 EP EP99964009A patent/EP1135166B9/en not_active Revoked
- 1999-12-01 DE DE69921178T patent/DE69921178T2/de not_active Expired - Lifetime
- 1999-12-01 AT AT99964009T patent/ATE279211T1/de active
- 1999-12-01 CA CA2352765A patent/CA2352765C/en not_active Expired - Fee Related
- 1999-12-01 IL IL14347499A patent/IL143474A0/xx active IP Right Grant
- 1999-12-01 AU AU20335/00A patent/AU763001B2/en not_active Ceased
- 1999-12-01 TR TR2001/02411T patent/TR200102411T2/xx unknown
- 1999-12-01 JP JP2000584928A patent/JP4971542B2/ja not_active Expired - Fee Related
- 1999-12-01 ES ES99964009T patent/ES2229800T3/es not_active Expired - Lifetime
- 1999-12-01 ME MEP-342/08A patent/MEP34208A/xx unknown
- 1999-12-01 RS YUP-396/01A patent/RS51273B/sr unknown
- 1999-12-01 PL PL349012A patent/PL199253B1/pl not_active IP Right Cessation
- 1999-12-01 CN CN200510092438A patent/CN100586481C/zh not_active Expired - Fee Related
- 1999-12-01 DK DK99964009T patent/DK1135166T3/da active
- 1999-12-01 WO PCT/US1999/028272 patent/WO2000032239A1/en active IP Right Grant
-
2001
- 2001-02-16 US US09/784,139 patent/US6518031B2/en not_active Expired - Fee Related
- 2001-05-25 NO NO20012589A patent/NO331998B1/no not_active IP Right Cessation
- 2001-05-31 IL IL143474A patent/IL143474A/en not_active IP Right Cessation
- 2001-05-31 ZA ZA200104477A patent/ZA200104477B/xx unknown
-
2002
- 2002-03-26 HK HK02102329.6A patent/HK1042428B/zh not_active IP Right Cessation
- 2002-06-29 HK HK02104914.3A patent/HK1043061B/zh not_active IP Right Cessation
- 2002-12-30 US US10/330,676 patent/US6773891B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 US US10/909,841 patent/US7247502B2/en not_active Expired - Fee Related
-
2006
- 2006-11-06 HK HK06112172.9A patent/HK1091415A1/xx not_active IP Right Cessation
-
2007
- 2007-07-20 US US11/780,742 patent/US7776620B2/en not_active Expired - Fee Related
-
2010
- 2010-07-14 US US12/836,165 patent/US8026109B2/en not_active Expired - Fee Related
- 2010-11-29 JP JP2010264835A patent/JP2011079849A/ja active Pending
-
2011
- 2011-05-13 US US13/107,460 patent/US20110217320A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100610A1 (ru) | Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты) | |
BR9711580A (pt) | Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes | |
DE60234782D1 (de) | Behandlungsverfahren mit liganden-immunogenkonjugaten | |
EA200100939A1 (ru) | Продолжительно действующие инсулинотропные пептиды | |
EA200301222A1 (ru) | Легочное введение химически модифицированного инсулина | |
ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
ATE109008T1 (de) | T-zellen-epitope als träger für einen konjugierten impfstoff. | |
CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
EA200201042A1 (ru) | Способ лечения с использованием конъюгатов лиганд-иммуноген | |
EA200300503A1 (ru) | Новые лекарственные композиции на основе солей тиотропия и солей салметерола | |
NZ314058A (en) | Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer | |
DK1329226T3 (da) | Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug | |
EP1329226A3 (en) | Hapten-Carrier Conjugates for use in Drug Abuse Therapy | |
PT97423A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias | |
DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
WO2002038611A3 (en) | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins | |
DE60234858D1 (de) | Polyalkylenoxid-Konjugate von thiolhaltigen Arzneistoffen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change in name of an applicant in a eurasian application | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |